<DOC>
	<DOCNO>NCT02654080</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability HIV-1 nef/tat/vif , env pDNA vaccine deliver electroporation ( EP ) , follow recombinant vesicular stomatitis virus ( rVSV ) HIV envC vaccine boost , healthy , HIV-uninfected adult .</brief_summary>
	<brief_title>Evaluating Safety , Tolerability , Immunogenicity Prime-Boost Regimen HIV-1 Nef/Tat/Vif , Env pDNA Vaccine Delivered Intramuscularly With Electroporation HIV-1 rVSV envC Vaccine Healthy , HIV-Uninfected Adults</brief_title>
	<detailed_description>This study evaluate safety tolerability HIV-1 nef/tat/vif , env pDNA vaccine deliver EP , follow rVSV HIV envC vaccine boost , healthy , HIV-uninfected adult . Participants randomly assign one two group . Participants Group 1 receive HIV-1 nef/tat/vif , env pDNA vaccine Day 0 Months 1 3 , follow rVSV HIV envC vaccine boost Months 6 9 . Participants Group 2 receive placebo vaccine Day 0 Months 1 , 3 , 6 , 9 . Study visit occur Day 0 , Week 2 , Months 1 , 1.5 , 3 , 3.25 , 3.5 , 6 , 6.25 , 6.5 , 9 , 9.25 , 9.5 , 12 , 15 . Visits may include physical examination , urine collection , blood collection , HIV testing , risk reduction counseling , assessment , questionnaire . Participants contact study staff follow-up monitoring annually 3 year follow initial study injection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>General Demographic Criteria : Age 18 50 year Access participate HIV Vaccine Trials Network ( HVTN ) clinical research site ( CRS ) willingness follow plan duration study Ability willingness provide inform consent Assessment understanding : volunteer demonstrate understand study ; complete questionnaire prior first vaccination verbal demonstration understand questionnaire item answer incorrectly Willing contact annually completion schedule clinic visit total 3 year follow initial study injection Agrees enroll another study investigational research agent prior completion last require protocol clinic visit ( excludes annual health contact safety surveillance ) Good general health show medical history , physical exam , screen laboratory test HIVRelated Criteria : Willingness receive HIV test result Willingness discuss HIV infection risk amenable HIV risk reduction counsel Assessed clinic staff `` low risk '' HIV infection commit maintain behavior consistent low risk HIV exposure last require protocol clinic visit Laboratory Inclusion Values : Hemogram/Complete Blood Count ( CBC ) : Hemoglobin great equal 11.0 g/dL volunteer bear female , great equal 13.0 g/dL volunteer bear male White blood cell count equal 3,300 12,000 cells/mm^3 Total lymphocyte count great equal 800 cells/mm^3 Remaining differential either within institutional normal range site physician approval Platelets equal 125,000 550,000/mm^3 Chemistry : Chemistry panel : ALT , AST , alkaline phosphatase less 1.25 time institutional upper limit normal ; creatinine le equal institutional upper limit normal ; CPK le equal 2.0 time institutional upper limit normal Virology : Negative HIV1 2 blood test : U.S. volunteer must negative FDAapproved enzyme immunoassay ( EIA ) Negative hepatitis B surface antigen ( HBsAg ) Negative antihepatitis C virus antibody ( antiHCV ) , negative HCV polymerase chain reaction ( PCR ) antiHCV positive Urine : Normal urine : Negative urine glucose , Negative trace urine protein , Negative trace urine hemoglobin ( trace hemoglobin present dipstick , microscopic urinalysis red blood cell level within institutional normal range ) Reproductive Status : Volunteers bear female : negative serum urine beta human chorionic gonadotropin ( βHCG ) pregnancy test perform prior vaccination day initial vaccination . Persons NOT reproductive potential due undergone total hysterectomy bilateral oophorectomy ( verified medical record ) , require undergo pregnancy test . Reproductive status : A volunteer bear female must : Agree consistently use effective contraception ( see protocol information ) sexual activity could lead pregnancy least 21 day prior enrollment last require protocol clinic visit . Effective contraception define use follow method : Condoms ( male female ) without spermicide , Diaphragm cervical cap spermicide , Intrauterine device ( IUD ) , Hormonal contraception , Any contraceptive method approve HVTN 112 Protocol Safety Review Team ( PSRT ) , Successful vasectomy male partner ( consider successful volunteer report male partner [ 1 ] documentation azoospermia microscopy , [ 2 ] vasectomy 2 year ago resultant pregnancy despite sexual activity postvasectomy ) ; Or reproductive potential , reach menopause ( menses 1 year ) undergone hysterectomy , bilateral oophorectomy , tubal ligation ; Or sexually abstinent . Volunteers born female must also agree seek pregnancy alternative method , artificial insemination vitro fertilization last require protocol clinic visit General : Allergy amidetype local anesthetic ( bupivacaine [ Marcaine ] , lidocaine [ Xylocaine ] , mepivacaine [ Polocaine/Carbocaine ] , etidocaine [ Duranest ] , prilocaine [ Citanest , EMLA® cream ] ) Presence implant electronic medical device ( e.g. , pacemaker , implantable cardioverter defibrillator ) Presence surgical traumatic metal implant upper limb and/or upper torso Sinus bradycardia ( define less 50 bpm exam ) history cardiac arrhythmia : e.g. , supraventricular tachycardia , atrial fibrillation , frequent ectopy Neurological neuropsychiatric disorder may interfere assessment safety : e.g. , frequent recur headache ( i.e. , pattern great 1 headache per month affect activity daily live ( ADLs ) /work , frequent severe/complicated migraine , cluster headache ) , chronic pain syndrome , dizziness , history meningitis encephalitis , cranial/spinal/peripheral neuropathy , limb weakness paralysis , movement disorder , narcolepsy , stroke sequela , moderate/severe major depressive disorder , moderate/severe bipolar disorder Deltoid skin fold measurement caliper great 40 mm Blood product receive within 120 day first vaccination Investigational research agent receive within 30 day first vaccination Body mass index ( BMI ) great equal 40 ; BMI great equal 35 2 following : age great 45 , systolic blood pressure great 140 mm Hg , diastolic blood pressure great 90 mm Hg , current smoker , know hyperlipidemia Intent participate another study investigational research agent study require nonHVTN HIV antibody test plan duration HVTN 112 study Pregnant breastfeed Active duty reserve U.S. military personnel Vaccines Other Injections : HIV vaccine ( ) receive prior HIV vaccine trial . For volunteer receive control/placebo HIV vaccine trial , HVTN 112 PSRT determine eligibility casebycase basis . NonHIV experimental vaccine ( ) receive within last 5 year prior vaccine trial . Exceptions may make vaccine subsequently undergone licensure FDA . For volunteer receive control/placebo experimental vaccine trial , HVTN 112 PSRT determine eligibility casebycase basis . For volunteer receive experimental vaccine ( ) great 5 year ago , eligibility enrollment determine HVTN 112 PSRT casebycase basis . Live attenuate vaccine influenza vaccine receive within 30 day first vaccination schedule within 28 day injection ( e.g. , measles , mumps , rubella [ MMR ] ; oral polio vaccine [ OPV ] ; varicella ; yellow fever ) Influenza vaccine vaccine live attenuate vaccine receive within 14 day prior first vaccination ( e.g. , tetanus , pneumococcal , hepatitis A B ) Allergy treatment antigen injection within 30 day first vaccination schedule within 14 day first vaccination Immune System : Immunosuppressive medication receive within 168 day first vaccination . ( Not exclusionary : [ 1 ] corticosteroid nasal spray ; [ 2 ] inhaled corticosteroid ; [ 3 ] topical corticosteroid mild , uncomplicated dermatitis ; [ 4 ] single course oral/parenteral corticosteroid dose less 2 mg/kg/day length therapy le 11 day completion least 30 day prior enrollment . ) Serious adverse reaction vaccine vaccine component , include history anaphylaxis relate symptom hive , respiratory difficulty , angioedema , and/or abdominal pain . ( Not exclude participation : volunteer nonanaphylactic adverse reaction pertussis vaccine child . ) Immunoglobulin receive within 90 day first vaccination Autoimmune disease Immunodeficiency Clinically Significant Medical Conditions : Untreated incompletely treat syphilis infection Clinically significant medical condition , physical examination finding , clinically significant abnormal laboratory result , past medical history clinically significant implication current health . A clinically significant condition process include limit : A process would affect immune response , A process would require medication affect immune response , Any contraindication repeat injection blood draw , A condition require active medical intervention monitoring avert grave danger volunteer 's health wellbeing study period , A condition process sign symptom could confuse reaction vaccine , Any condition specifically list among exclusion criterion . Any medical , psychiatric , occupational , condition , judgment investigator , would interfere , serve contraindication , protocol adherence , assessment safety reactogenicity , volunteer 's ability give inform consent Psychiatric condition precludes compliance protocol . Specifically excluded person psychosis within past 3 year , ongoing risk suicide , history suicide attempt gesture within past 3 year Current antituberculosis ( TB ) prophylaxis therapy Asthma mild , wellcontrolled asthma . ( Symptoms asthma severity define recent National Asthma Education Prevention Program ( NAEPP ) Expert Panel report ) . Exclude volunteer : Uses shortacting rescue inhaler ( typically beta 2 agonist ) daily , Uses moderate/high dose inhaled corticosteroid , In past year either follow : Greater 1 exacerbation symptom treat oral/parenteral corticosteroid ; Needed emergency care , urgent care , hospitalization , intubation asthma . Diabetes mellitus type 1 type 2 , include case control diet alone . ( Not exclude : history isolate gestational diabetes . ) Thyroidectomy , thyroid disease require medication last 12 month Hypertension : If person find elevate blood pressure hypertension screen previously , exclude blood pressure well control . Wellcontrolled blood pressure define consistently less equal 140 mm Hg systolic less equal 90 mm Hg diastolic , without medication , isolate , brief instance high reading , must less equal 150 mm Hg systolic less equal 100 mm Hg diastolic . For volunteer , blood pressure must less equal 140 mm Hg systolic less equal 90 mm Hg diastolic enrollment . If person NOT find elevate blood pressure hypertension screen previously , exclude systolic blood pressure great equal 150 mm Hg enrollment diastolic blood pressure great equal 100 mm Hg enrollment . Bleeding disorder diagnose doctor ( e.g. , factor deficiency , coagulopathy , platelet disorder require special precaution ) Malignancy ( Not exclude participation : Volunteer malignancy excise surgically , investigator 's estimation , reasonable assurance sustain cure . unlikely experience recurrence malignancy period study ) Seizure disorder : History seizure ( ) within past three year . Also exclude volunteer use medication order prevent treat seizure ( ) time within past 3 year . Asplenia : condition result absence functional spleen History hereditary angioedema , acquire angioedema , idiopathic angioedema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>